Cited by 1,167SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 epidemiological studies

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Open access

Tartof, Sara Y, Slezak, Jeff M, Fischer, Heidi, Hong, Vennis, Ackerson, Bradley K, Ranasinghe, Omesh N, Frankland, Timothy B, Ogun, Oluwaseye A, Zamparo, Joann M, Gray, Sharon, Valluri, Srinivas R, Pan, Kaije, Angulo, Frederick J, Jodar, Luis, McLaughlin, John M·2021·The Lancet

DOI 10.1016/s0140-6736(21)02183-8PMC PMC8489881

Open this paper in CoChat — free account Open PDF

Abstract

Background Vaccine effectiveness studies have not differentiated the effect of the delta (B.1.617.2) variant and potential waning immunity in observed reductions in effectiveness against SARS-CoV-2 infections. We aimed to evaluate overall and variant-specific effectiveness of BNT162b2 (tozinameran, Pfizer-BioNTech) against SARS-CoV-2 infections and COVID-19-related hospital admissions by time since vaccination among members of a large US health-care system. Methods In this retrospective cohort study, we analysed electronic health records of individuals (≥12 years) who were members of the health-care organisation Kaiser Permanente Southern California (CA, USA), to assess BNT162b2 vaccine effectiveness against SARS-CoV-2 infections and COVID-19-related hospital admissions for up to 6 months. Participants were required to have 1 year or more previous membership of the organisation. Outcomes comprised SARS-CoV-2 PCR-positive tests and COVID-19-related hospital admissions. Effectiveness calculations were based on hazard ratios from adjusted Cox models. This study was registered with ClinicalTrials.gov, NCT04848584. Findings Between Dec 14, 2020, and Aug 8, 2021, of 4 920 549 individuals assessed for eligibility, we included 3 436 957 (median age 45 years [IQR 29-61]; 1 799 395 [52·4%] female and 1 637 394 [47·6%] male). For fully vaccinated individuals, effectiveness against SARS-CoV-2 infections was 73% (95% CI 72-74) and against COVID-19-related hospital admissions was 90% (89-92). Effectiveness against infections declined from 88% (95% CI 86-89) during the first month after full vaccination to 47% (43-51) after 5 months. Among sequenced infections, vaccine effectiveness against infections of the delta variant was high during the first month after full vaccination (93% [95% CI 85-97]) but declined to 53% [39-65] after 4 months. Effectiveness against other (non-delta) variants the first month after full vaccination was also high at 97% (95% CI 95-99), but waned to 67% (45-80) at 4-5 months. Vaccine effectiveness against hospital admissions for infections with the delta variant for all ages was high overall (93% [95% CI 84-96]) up to 6 months. Interpretation Our results provide support for high effectiveness of BNT162b2 against hospital admissions up until around 6 months after being fully vaccinated, even in the face of widespread dissemination of the delta variant. Reduction in vaccine effectiveness against SARS-CoV-2 infections over time is probably primarily due to waning immunity with time rather than the delta variant escaping vaccine protection. Funding Pfizer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)02183-8

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · doi:10.1101/2021.07.28.21261159 · Cited by 1,640
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110345 · Cited by 1,640
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564
Self-citation
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
The Development of a Standardized Neighborhood Deprivation Index
Messer, L. C., Laraia, B. A., Kaufman, J. S., Eyster, J. T., Holzman, C., Culhane, J. F., Elo, I. T., Burke, J. G., & O'Campo, P. J. (2006) · Journal of Urban Health · doi:10.1007/s11524-006-9094-x · Cited by 1,046
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.
Sheikh, A., McMenamin, J., Taylor, B., & Robertson, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01358-1 · Cited by 939

Show all 37 references

Research works printed but not linked: 1

Lopez Bernal, 2021, Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant, N Engl J Med, 385, 585, 10.1056/NEJMoa2108891 · DOI · Paper page

Sorted by citations

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic
Karim, S. S. A., & Karim, Q. A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02758-6 · Cited by 1,302
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression
Feikin, D. R., Higdon, M. M., Abu-Raddad, L. J., Andrews, N., Araos, R., Goldberg, Y., Groome, M. J., Huppert, A., O'Brien, K. L., Smith, P. G., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00152-0 · Cited by 1,237
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
Fiolet, T., Kherabi, Y., MacDonald, C.-J., Ghosn, J., & Peiffer-Smadja, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.005 · Cited by 911
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
Goel, R. R., Painter, M. M., Apostolidis, S. A., Mathew, D., Meng, W., Rosenfeld, A. M., Lundgreen, K. A., Reynaldi, A., Khoury, D. S., Pattekar, A., et al. (2021) · Science · doi:10.1126/science.abm0829 · Cited by 873
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection
Hall, V., Foulkes, S., Insalata, F., Kirwan, P., Saei, A., Atti, A., Wellington, E., Khawam, J., Munro, K., Cole, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2118691 · Cited by 711
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
Munro, A. P. S., Janani, L., Cornelius, V. R., Aley, P. K., Babbage, G., Baxter, D. N., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02717-3 · Cited by 656
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants
Accorsi, E. K., Britton, A., Fleming-Dutra, K. E., Smith, Z. R., Shang, N., Derado, G., Miller, J., Schrag, S. J., & Verani, J. R. (2022) · JAMA · doi:10.1001/jama.2022.0470 · Cited by 628
Humoral and cellular immune memory to four COVID-19 vaccines
Zhang, Z., Mateus, J., Coelho, C. H., Dan, J. M., Moderbacher, C. R., Gálvez, R. I., Côrtes, F. H., Grifoni, A., Tarke, A., Chang, J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.05.022 · Cited by 576
Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2
Goldberg, Y., Mandel, M., Bar‐On, Y. M., Bodenheimer, O., Freedman, L. S., Ash, N., Alroy‐Preis, S., Huppert, A., & Milo, R. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2118946 · Cited by 472
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
Tang, P., Hasan, M. R., Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., AlMukdad, S., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01583-4 · Cited by 450
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
Munro, A., Janani, L., Cornelius, V. R., Aley, P. K., Babbage, G., Baxter, D. N., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., et al. (2021) · Repository@Nottingham (University of Nottingham) · doi:10.1016/s0140-6736%2821%2902717-3 · Cited by 439
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Ferdinands, J. M., Rao, S., Dixon, B. E., Mitchell, P. K., DeSilva, M. B., Irving, S. A., Lewis, N., Natarajan, K., Stenehjem, E., Grannis, S. J., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7107e2 · Cited by 435
Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California
Lewnard, J. A., Hong, V. X., Patel, M. M., Kahn, R. J., Lipsitch, M., & Tartof, S. Y. (2022) · Nature Medicine · doi:10.1038/s41591-022-01887-z · Cited by 394
Self-citation
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Tang, P., Hasan, M. R., Coyle, P., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2200797 · Cited by 380
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
Moreira, E. D., Kitchin, N., Xu, X., Dychter, S. S., Lockhart, S., Gurtman, A., Perez, J. L., Zerbini, C. A. F., Dever, M. E., Jennings, T. W., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2200674 · Cited by 348
Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina
Lin, D.-Y., Gu, Y., Wheeler, B., Young, H., Holloway, S. T., Sunny, S.-K., Moore, Z., & Zeng, D. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2117128 · Cited by 364
SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
Lipsitch, M., Krammer, F., Regev‐Yochay, G., Lustig, Y., & Balicer, R. D. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00662-4 · Cited by 345
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
Zeng, G., Wu, Q., Pan, H., Li, M., Yang, J., Wang, L., Wu, Z., Jiang, D., Deng, X., Chu, K., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00681-2 · Cited by 319
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study
Menni, C., May, A., Polidori, L., Louca, P., Wolf, J., Pujol, J. C., Hu, C. Y., Sebastien Ourselin, A., Steves, C. J., Valdes, A. M., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00146-3 · Cited by 329
Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants
Bates, T. A., McBride, S. K., Leier, H. C., Guzman, G., Lyski, Z. L., Schoen, D., Winders, B., Lee, J., Lee, D. X., Messer, W. B., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abn8014 · Cited by 293
Effectiveness of Covid-19 Vaccination Against Risk of Symptomatic Infection, Hospitalization, and Death Up to 9 Months: A Swedish Total-Population Cohort Study
Nordström, P., Ballin, M., & Nordström, A. (2021) · The Lancet · doi:10.1016/s0140-6736(22)00089-7 · Cited by 341
SARS-CoV-2 Variants, Vaccines, and Host Immunity
Mistry, P., Barmania, F., Mellet, J., Peta, K. T., Strydom, A., Viljoen, I. M., James, W., Gordon, S., & Pepper, M. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.809244 · Cited by 314
The changing epidemiology of SARS-CoV-2
Koelle, K., Martin, M. A., Antia, R., Lopman, B. A., & Dean, N. E. (2022) · Science · doi:10.1126/science.abm4915 · Cited by 308
Correlates of protection against SARS ‐ CoV ‐2 infection and COVID‐19 disease
Goldblatt, D., Alter, G., Crotty, S., & Plotkin, S. A. (2022) · Immunological Reviews · doi:10.1111/imr.13091 · Cited by 301
Evaluation of Waning of SARS-CoV-2 Vaccine–Induced Immunity: A Systematic Review and Meta-analysis
Menegale, F., Manica, M., Zardini, A., Guzzetta, G., Marziano, V., d'Andrea, V., Trentini, F., Ajelli, M., Poletti, P., & Merler, S. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.10650 · Cited by 280
Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis
Zeng, B., Gao, L., Zhou, Q., Yu, K., & Sun, F. (2022) · BMC Medicine · doi:10.1186/s12916-022-02397-y · Cited by 289
Immunological memory to SARS‐CoV ‐2 infection and COVID ‐19 vaccines
Sette, A., & Crotty, S. (2022) · Immunological Reviews · doi:10.1111/imr.13089 · Cited by 270
SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis
Ssentongo, P., Ssentongo, A. E., Voleti, N., Groff, D., Sun, A., Ba, D. M., Nunez, J., Parent, L. J., Chinchilli, V. M., & Paules, C. I. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07418-y · Cited by 260
Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies
Shah, M., & Woo, H. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.830527 · Cited by 253
SARS-CoV-2 vaccine protection and deaths among US veterans during 2021
Cohn, B. A., Cirillo, P. M., Murphy, C. C., Krigbaum, N. Y., & Wallace, A. W. (2021) · Science · doi:10.1126/science.abm0620 · Cited by 233
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines
Wei, J., Pouwels, K. B., Stoesser, N. E., Matthews, P. C., Diamond, I. D., Studley, R., Rourke, E. D., Cook, D., Bell, J. I., Newton, J. N., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01721-6 · Cited by 248
Accelerating ionizable lipid discovery for mRNA delivery using machine learning and combinatorial chemistry
Li, B., Raji, I. O., Gordon, A. G. R., Sun, L., Raimondo, T. M., Oladimeji, F. A., Jiang, A. Y., Varley, A., Langer, R. S., & Anderson, D. G. (2024) · Nature Materials · doi:10.1038/s41563-024-01867-3 · Cited by 236
Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection
Evans, J. P., Zeng, C., Carlin, C., Lozanski, G., Saif, L. J., Oltz, E. M., Gumina, R. J., & Liu, S. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn8057 · Cited by 239
BNT162b2 Protection against the Omicron Variant in Children and Adolescents
Price, A. M., Olson, S. M., Newhams, M. M., Halasa, N., Boom, J. A., Sahni, L. C., Pannaraj, P. S., Irby, K., Bline, K., Maddux, A. B., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202826 · Cited by 229
BNT162b2 vaccination induces durable SARS-CoV-2–specific T cells with a stem cell memory phenotype
Guerrera, G., Picozza, M., D’Orso, S., Placido, R., Pirronello, M., Verdiani, A., Termine, A., Fabrizio, C., Giannessi, F., Sambucci, M., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abl5344 · Cited by 230
Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study
Bruxvoort, K. J., Sy, L. S., Qian, L., Ackerson, B. K., Luo, Y., Lee, G. S., Tian, Y., Florea, A., Aragones, M., Tubert, J. E., et al. (2021) · BMJ · doi:10.1136/bmj-2021-068848 · Cited by 230
Self-citation
A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson
Patel, R. S., Kaki, M., Potluri, V., Kahar, P., & Khanna, D. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.2002083 · Cited by 252
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Chi, W.-Y., Li, Y.-D., Huang, H., Chan, T. E. H., Chow, S.-Y., Su, J.-H., Ferrall, L., Hung, C., & Wu, T. ‐. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00853-8 · Cited by 225
The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis
Rahmani, K., Shavaleh, R., Forouhi, M., Disfani, H. F., Kamandi, M., Oskooi, R. K., Foogerdi, M., Soltani, M., Rahchamani, M., Mohaddespour, M., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.873596 · Cited by 218
Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents
Olson, S. M., Newhams, M. M., Halasa, N., Price, A. M., Boom, J. A., Sahni, L. C., Pannaraj, P. S., Irby, K., Walker, T. C., Schwartz, S. P., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2117995 · Cited by 196
The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines
McLean, G. R., Kamil, J. P., Lee, B., Moore, P. L., Schulz, T. F., Muik, A., Şahin, U., Türeci, Ö., & Pather, S. (2022) · mBio · doi:10.1128/mbio.02979-21 · Cited by 193
Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study
Ferdinands, J. M., Rao, S., Dixon, B. E., Mitchell, P. K., DeSilva, M. B., Irving, S. A., Lewis, N., Natarajan, K., Stenehjem, E., Grannis, S. J., et al. (2022) · BMJ · doi:10.1136/bmj-2022-072141 · Cited by 185
Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy
Haque, A., & Pant, A. B. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2021.102792 · Cited by 189
Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events
Ng, S. C., Peng, Y., Zhang, L., Mok, C. K. P., Zhao, S., Li, A., Ching, J. Y. L., Liu, Y., Yan, S., Chan, D. L. S., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-326563 · Cited by 186
Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada
Skowronski, D. M., Febriani, Y., Ouakki, M., Setayeshgar, S., El Adam, S., Zou, M., Talbot, D., Prystajecky, N., Tyson, J. R., Gilca, R., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac290 · Cited by 155
Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance
Fleming-Dutra, K. E., Britton, A., Shang, N., Derado, G., Link‐Gelles, R., Accorsi, E. K., Smith, Z., Miller, J., Verani, J. R., & Schrag, S. J. (2022) · JAMA · doi:10.1001/jama.2022.7493 · Cited by 144
Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France
Grant, R., Charmet, T., Schaeffer, L., Galmiche, S., Madec, Y., Platen, C. V., Chény, O., Omar, F., David, C., Rogoff, A., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100278 · Cited by 147
Temporal changes in factors associated with COVID-19 vaccine hesitancy and uptake among adults in Hong Kong: Serial cross-sectional surveys
Xiao, J., Cheung, J. K., Wu, P., Ni, M. Y., Cowling, B. J., & Liao, Q. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100441 · Cited by 146
Duration of Effectiveness of Vaccines Against SARS-CoV-2 Infection and COVID-19 Disease: Results of a Systematic Review and Meta-RegressionPreprint
Feikin, D. R., Higdon, M. M., Abu-Raddad, L. J., Andrews, N. J., Rafael Araos, B., Goldberg, Y., Groome, M. J., Huppert, A., O’Brien, K. L., Smith, P. G., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3961378 · Cited by 144
Effectiveness of heterologous and homologous COVID-19 vaccine regimens: living systematic review with network meta-analysis
Au, W. Y., & Cheung, P. P.-H. (2022) · BMJ · doi:10.1136/bmj-2022-069989 · Cited by 143
COVID‐19 vaccinations: The unknowns, challenges, and hopes
Mohamed, K., Rzymski, P., Islam, M. S., Makuku, R., Mushtaq, A., Khan, A., Ivanovska, M., Makka, S. A., Hashem, F., Marquez, L. P., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27487 · Cited by 150
BNT162b2 (Pfizer–Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design
Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V. X., Xie, F., Ackerson, B. K., Valluri, S. R., Jódar, L., & McLaughlin, J. M. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00101-1 · Cited by 151
Self-citation
Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?
Kent, S. J., Khoury, D. S., Reynaldi, A., Juno, J. A., Wheatley, A. K., Stadler, E., John Wherry, E., Triccas, J., Sasson, S. C., Cromer, D., et al. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00716-1 · Cited by 139
COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant and implications for vaccination
Yang, W., & Shaman, J. L. (2022) · Journal of The Royal Society Interface · doi:10.1098/rsif.2021.0900 · Cited by 141
Estimated Number of COVID-19 Infections, Hospitalizations, and Deaths Prevented Among Vaccinated Persons in the US, December 2020 to September 2021
Steele, M. K., Couture, A., Reed, C., Iuliano, A. D., WHITAKER, M. D., Fast, H. E., Hall, A. J., MacNeil, A., Cadwell, B. L., Marks, K. J., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.20385 · Cited by 137
Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021
Harder, T., Külper‐Schiek, W., Reda, S. A., Treskova, M., Koch, J., Vygen-Bonnet, S., & Wichmann, O. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.41.2100920 · Cited by 135
Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?
Milne, G., Hames, T., Scotton, C. J., Gent, N., Johnsen, A., Anderson, R. M., & Ward, T. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00407-0 · Cited by 122
Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil
Katikireddi, S. V., Cerqueira-Silva, T., Vasileiou, E., Robertson, C., Amele, S., Pan, J., Taylor, B., Boaventura, V., Werneck, G. L., Flores-Ortiz, R., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02754-9 · Cited by 124
SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance — Los Angeles County, California, November 7, 2021–January 8, 2022
Danza, P. Y., Koo, T. H., Haddix, M., Fisher, R. L., Traub, E., OYong, K., & Balter, S. E. (2022) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7105e1 · Cited by 119
SARS-CoV-2 Variant Delta Rapidly Displaced Variant Alpha in the United States and Led to Higher Viral Loads
Bolze, A., Luo, S., White, S. J., Cirulli, E. T., Wyman, D., Rossi, A. D., Machado, H., Cassens, T., Jacobs, S., Barrett, K. M. S., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100564 · Cited by 115
Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study
Adams, K., Rhoads, J. P., Surie, D., Gaglani, M., Ginde, A. A., McNeal, T., Talbot, H. K., Casey, J. D., Zepeski, A., Shapiro, N. I., et al. (2022) · BMJ · doi:10.1136/bmj-2022-072065 · Cited by 115
The effect of COVID certificates on vaccine uptake, health outcomes, and the economy
Oliu‐Barton, M., Pradelski, B., Woloszko, N., Guetta-Jeanrenaud, L., Aghion, P., Artus, P., Fontanet, A. L., Martin, P. J., & Wolff, G. B. (2022) · Nature Communications · doi:10.1038/s41467-022-31394-1 · Cited by 130
Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study
Fabiani, M., Puopolo, M., Morciano, C., Spuri, M., Alegiani, S. S., Filia, A., D’Ancona, F. “., Manso, M. D., Riccardo, F., Tallon, M., et al. (2022) · BMJ · doi:10.1136/bmj-2021-069052 · Cited by 111
Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study
Izikson, R., Brune, D., Bolduc, J.-S., Bourron, P., Fournier, M., Moore, T. M., Pandey, A., Perez, L., Sater, N., Shrestha, A., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00557-9 · Cited by 112
COVID-19 Vaccine Booster Hesitancy (VBH) of Healthcare Workers in Czechia: National Cross-Sectional Study
Klugar, M., Riad, A., Mohanan, L., & Pokorná, A. (2021) · Vaccines · doi:10.3390/vaccines9121437 · Cited by 110
COVID-19 vaccine breakthrough infections
Gupta, R. K., & Topol, E. J. (2021) · Science · doi:10.1126/science.abl8487 · Cited by 105
Effectiveness of a Third Dose of BNT162b2 mRNA COVID-19 Vaccine in a Large US Health System: A Retrospective Cohort Study
Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V. X., Frankland, T. B., Ackerson, B. K., Takhar, H. S., Ogun, O. A., Simmons, S. R., Zamparo, J. M., et al. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100198 · Cited by 107
Self-citation
Untangling the changing impact of non-pharmaceutical interventions and vaccination on European COVID-19 trajectories
Ge, Y., Zhang, W., Wu, X., Ruktanonchai, C. W., Liu, H., Wang, J., Song, Y., Liu, M., Yan, W., Yang, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30897-1 · Cited by 108
COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies
Fusco, M. D., Lin, J., Vaghela, S., Lingohr-Smith, M., Nguyen, J. L., Sforzolini, T. S., Judy, J., Cane, A. D., & Moran, M. M. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2035222 · Cited by 106
Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions
Dhawan, M. K., Sharma, A., Choudhary, P., Thakur, N., Rajkhowa, T. K., & Choudhary, O. P. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2068883 · Cited by 116
Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years — United States, June–September 2021
Olson, S. M., Newhams, M. M., Halasa, N., Price, A. M., Boom, J. A., Sahni, L. C., Irby, K., Walker, T. C., Schwartz, S. P., Pannaraj, P. S., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7042e1 · Cited by 101
Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose
Lustig, Y., Gonen, T., Meltzer, L., Gilboa, M., Indenbaum, V., Cohen, C., Amit, S., Jaber, H., Doolman, R., Asraf, K., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01212-3 · Cited by 95
Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults — United States, August–December 2021
Tenforde, M. W., Patel, M. M., Gaglani, M., Ginde, A. A., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A. E., McNeal, T., et al. (2022) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7104a2 · Cited by 94
Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study
Lee, L. Y. W., Starkey, T., Ionescu, M. C., Little, M., Tilby, M., Tripathy, A. R., McKenzie, H., Hajji, Y. A., Barnard, M., Benny, L., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00202-9 · Cited by 96
Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies
Chung, Y.-S., Lam, C.-Y., Tan, P.-H., Tsang, H. F., & Wong, S. C. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158155 · Cited by 116
Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance
Britton, A., Fleming-Dutra, K. E., Shang, N., Smith, Z., Dorji, T., Derado, G., Accorsi, E. K., Ajani, U. A., Miller, J., Schrag, S. J., et al. (2022) · JAMA · doi:10.1001/jama.2022.2068 · Cited by 84
Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review
Perry, J. A., Osman, S., Wright, J., Richard‐Greenblatt, M., Buchan, S. A., Sadarangani, M., & Bolotin, S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266852 · Cited by 93
Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
Kanokudom, S., Assawakosri, S., Suntronwong, N., Auphimai, C., Nilyanimit, P., Vichaiwattana, P., Thongmee, T., Yorsaeng, R., Srimuan, D., Thatsanatorn, T., et al. (2022) · Vaccines · doi:10.3390/vaccines10010086 · Cited by 82
Viral Load Among Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Persons Infected With the SARS-CoV-2 Delta Variant
Acharya, C. B., Schrom, J., Mitchell, A. M., Coil, D. A., Marquez, C., Rojas, S., Wang, C., Liu, J., Pilarowski, G. O. W., Solis, L. J., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac135 · Cited by 86
Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals
Muena, N. A., García‐Salum, T., Pardo‐Roa, C., Avendaño, M. J., Serrano, E. F., Lévican, J., Almonacid, L. I., Valenzuela, G. H., Poblete, E., Strohmeier, S., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103972 · Cited by 85
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper
Marjot, T., Eberhardt, C. S., Boettler, T., Belli, L. S., Berenguer, M., Buti, M., Jalan, R., Mondelli, M. U., Moreau, R., Shouval, D., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.008 · Cited by 84
Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods
Link‐Gelles, R., Levy, M. E., Natarajan, K., Reese, S. E., Naleway, A. L., Grannis, S. J., Klein, N. P., DeSilva, M. B., Ong, T. C., Gaglani, M., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.2598 · Cited by 92
Screening and vaccination against COVID-19 to minimise school closure: a modelling study
Colosi, E., Bassignana, G., Contreras, D. A., Poirier, C., Boëlle, P., Cauchemez, S., Yazdanpanah, Y., Lina, B., Fontanet, A. L., Barrat, A., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00138-4 · Cited by 82
Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study
Monge, S., Rojas-Benedicto, A., Olmedo, C., Mazagatos, C., José Sierra, M., Limia, A., Martín-Merino, E., Larrauri, A., Hernán, M. A., Moreno, D., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00292-4 · Cited by 81
SARS-CoV-2 evolution on a dynamic immune landscape
Raharinirina, N. A., Gubela, N., Börnigen, D., Smith, M. R., Oh, D., Budt, M., Mache, C., Schillings, C., Fuchs, S., Dürrwald, R., et al. (2025) · Nature · doi:10.1038/s41586-024-08477-8 · Cited by 88
Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
Suah, J. L., Husin, M., Tok, P. S. K., Tng, B. H., Thevananthan, T., Low, E. V., Appannan, M. R., Muhamad Zin, F., Mohd Zin, S., Yahaya, H., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.03.028 · Cited by 76
Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination
Gao, Y., Cai, C., Wullimann, D., Niessl, J., Rivera‐Ballesteros, O., Chen, P., Lange, J., Cuapio, A., Blennow, O., Hansson, L., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.07.005 · Cited by 73
COVID-19 Vaccine Boosters: The Good, the Bad, and the Ugly
Rzymski, P., Camargo, C. A., Fal, A., Flisiak, R., Gwenzi, W., Kelishadi, R., Leemans, A., Nieto, J. J., Ozen, A., Perc, M., et al. (2021) · Vaccines · doi:10.3390/vaccines9111299 · Cited by 76
Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals
Maeda, K., Amano, M., Uemura, Y., Tsuchiya, K., Matsushima, T., Noda, K., Shimizu, Y., Fujiwara, A., Takamatsu, Y., Ichikawa, Y., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-01930-y · Cited by 72
Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges
Amanatidou, E., Gkiouliava, A., Pella, E., Serafidi, M., Tsilingiris, D., Vallianou, N. G., Karampela, Ι., & Dalamaga, Μ. (2022) · Metabolism Open · doi:10.1016/j.metop.2022.100180 · Cited by 78
Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections
Stærke, N. B., Reekie, J., Nielsen, H., Benfield, T., Wiese, L., Knudsen, L. S., Iversen, M. B., Iversen, K. K., Fogh, K., Bodilsen, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32254-8 · Cited by 74
Understanding Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination
Klompas, M. (2021) · JAMA · doi:10.1001/jama.2021.19063 · Cited by 78
Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine
Saciuk, Y., Kertes, J., Shamir-Stein, N., & Zohar, A. E. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab556 · Cited by 73
Effectiveness of BNT162b2 against COVID-19 in adolescents
Powell, A. A., Kirsebom, F., Stowe, J., McOwat, K., Saliba, V., Ramsay, M. E., Lopez-Bernal, J., Andrews, N., & Ladhani, S. N. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00177-3 · Cited by 69
Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case–control study
Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V. X., Frankland, T. B., Ackerson, B. K., Xie, F., Takhar, H. S., Ogun, O. A., Simmons, S. R., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00306-5 · Cited by 71
Self-citation
Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study)
Arashiro, T., Arima, Y., Muraoka, H., Sato, A., Oba, K., Uehara, Y., Arioka, H., Yanai, H., Kuramochi, J., Ihara, G., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciac635 · Cited by 70
BNT162b2 Vaccine‐Associated Myo/Pericarditis in Adolescents: A Stratified Risk‐Benefit Analysis
Krug, A., Stevenson, J., & Høeg, T. B. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13759 · Cited by 69
Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis
Castaldo, M., Waliszewska‐Prosół, M., Koutsokera, M., Robotti, M., Straburzyński, M., Apostolakopoulou, L., Capizzi, M., Çibuku, O., Ambat, F. D. F., Frattale, I., et al. (2022) · The Journal of Headache and Pain · doi:10.1186/s10194-022-01400-4 · Cited by 72
Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial
Heath, P. T., Galiza, E. P., Baxter, D. N., Boffito, M., Browne, D., Burns, F. M., Chadwick, D., Clark, R., Cosgrove, C. A., Galloway, J. B., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac803 · Cited by 70
Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study
Wright, B. J., Tideman, S., Diaz, G. A., French, T., Parsons, G., & Robicsek, A. A. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00042-x · Cited by 64

Authors: Tartof, S. Y., Slezak, J. M., Fischer, H., Hong, V., Ackerson, B. K., Ranasinghe, O. N., Frankland, T. B., Ogun, O. A., Zamparo, J. M., Gray, S., Valluri, S. R., Pan, K., Angulo, F. J., Jodar, L., & McLaughlin, J. M.
Affiliations: Kaiser Permanente (US)
Pfizer (United States) (US)
Corresponding author: Tartof, Sara Y
ORCID: Tartof, Sara Y
Slezak, Jeff M
Fischer, Heidi
Hong, Vennis
Ackerson, Bradley K
Ranasinghe, Omesh N
Frankland, Timothy B
Valluri, Srinivas R
Angulo, Frederick J
Venue: The Lancet
Publisher: Elsevier BV
Published: 2021-10
Volume: 398
Issue: 10309
Pages: 1407-1416
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(21)02183-8
PMC: PMC8489881
OpenAlex: W3202826390
Cited by: 1,167
References: 37
Citations by year: 2026: 33 · 2025: 70 · 2024: 116 · 2023: 257 · 2022: 583 · 2021: 108
FWCI: 84.33
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: The Lancet (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Pfizer Inc Boulder
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Social Sciences › Health › Vaccine Coverage and Hesitancy
Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
Keywords: BNT162b2, COVID-19 vaccines, mRNA vaccines, vaccine effectiveness, COVID-19 pandemic, COVID-19 hospitalization, Delta variant, waning immunity, integrated health system, Kaiser Permanente, time since vaccination, SARS-CoV-2 sequencing
MeSH terms: COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Aged, 80 and over, Child, Female, Hospitalization, Humans, Male, Middle Aged, Organizations, Retrospective Studies, RNA, Messenger, Time Factors, United States, Vaccination, Delivery of Health Care, Integrated

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks